Safety, Tolerability and Pharmacokinetics of Simmiparib in Patients With Malignant Advanced Solid Tumor

NCT02993913 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Advanced Solid Tumor

Interventions

DRUG: Simmiparib

Sponsor

Shanghai Acebright Pharmaceuticals Co., Ltd.